Here are Wednesday’s biggest calls on Wall Street:

UBS initiates CoreWeave as buy

UBS said it sees robust growth.

“ We are launching coverage of CoreWeave shares with a Buy rating and $120 PT (~40% upside to current price), extending our coverage of the AI infrastructure market beyond the hyperscalers and Oracle.”

KeyBanc initiates Guardian Pharmacy Services as overweight

Key said the company is “best-in-class.”

“Over the past 20 years, GRDN has established itself as a best-in-class long-term care (LTC) pharmacy focused on the assisted living facility (ALF) space.”

Wolfe reiterates Amazon as outperform

Wolfe raised its price target to $320 per share from $315.

“We are raising ests - our AWS revenue & OI are 8.5% & 3.9% above the Street, respectively. We think core AWS margin is underappreciated + we share our framework for Bedrock rev & margin (@50%) & revise Anthropic & OAI’s contributions. AMZN remains one of our top ’27 picks.”

BMO initiates HCA Healthcare as outperform

BMO said the company is resilient.

” HCA’s ongoing investments in attractive geographies with strong demographic tailwinds coupled with accumulating benefits from its ongoing ‘resiliency’ program should keep EBITDA compounding in line with its longer-term 4-6% targeted CAGR despite weathering one of the toughest macro backdrops the industry has faced in a while.”

Morgan Stanley reiterates SpaceX as overweight

Morgan Stanley said SpaceX is not a likely threat to the wireless companies right now.

“As a result, we believe SpaceX will have limited ability to access significant swaths of critical mid-band spectrum in urban areas. The lack of an imminent threat to the Big 3′s core markets could mean that any potential MVNO agreement may not happen until several years from now.”

Wells Fargo initiates Beta Bionics as overweight

Wells said the medtech diabetes company has a unique offering.

“We rate BBNX Overweight, $28 PT. Mint brings BBNX’s differentiated algorithm to the fast-growing patch-pump market, underpinning a ~38% revenue CAGR through 2030E, with pharmacy, T2D and pipeline tailwinds. Our PT is based on ~4x ’28E sales.”

Oppenheimer initiates Teva Pharmaceuticals as outperform

Oppenheimer said it sees growth upside.

“We initiate coverage of Teva with an Outperform rating and $50 PT.”

Bernstein initiates Amphenol and TE Connectivity as outperform

Bernstein said the interconnect industrial companies have plenty of upside.

“We are initiating coverage on the interconnect space, specifically on Ampehnol ( APH) and TE Connectivity (TEL).”

Rosenblatt reiterates Palantir as buy

The firm said it’s bullish on the FAA’s use of the company’s aircraft safety monitoring solution.

“We think the rollout Monday of the FAA’s SMART (Strategic Management of Airspace, Routes, and Trajectories) system highlights the FAA opportunity for Palantir. On Monday, the Federal Aviation Administration rolled out its artificial intelligence-powered tool to manage flights for the three major Washington-area airports, bringing the technology live for the first time in the U.S.”

UBS initiates Tera Wulf, Cipher Mining, Hut 8, Core Scientific and Applied Digital as buy

UBS initiated several bitcoin miners on Wednesday and says they have plenty of growth ahead.

“We are initiating coverage with Buy ratings on five data center stocks (HUT , WULF, APLD, CORZ, CIFR) positioned for rapid growth as AI adoption ramps and model developers’ ability to meet demand remains constrained.”

Seaport initiates Marvell as buy

Seaport said the company has a long runway for growth.

” Marvell (MRVL) has considerable growth ahead as its interconnect and custom silicon businesses enjoy their time in the AI sun.”

Stifel upgrades Microsoft to buy from hold

Stifel said the company is firing on all cylinders.

“Overall, MSFT clearly turned the corner post the June quarter print and with our growing sense the company can drive sustained strong Azure upside (200-300 bps) stemming from incremental capacity monetization, reduced LLM R & D intensity and accelerating OAI revenue contribution given the uptick in OAI’s business, we expect recent stock momentum to continue into 2H.”

Citi reiterates Micron as buy

Citi raised its price target on Micron ahead of earnings next week.

“We adjust our TP to $1,300 from $1,150 on consistent 8x P/E times revised CY27 EPS.”

Bank of America reiterates Apple as buy

The firm said its checks show iPhone lead times are “stable.”

“Our tracking of iPhone ship dates on Apple’s own website, and various carrier websites, indicates that as of Sep 21st (10 days after preorders started on Fri Sep 12th), ship time (in days) for the iPhone 18 Pro and Pro Max models are roughly similar to last year at this point in the pre-order cycle.”

JPMorgan upgrades BP to overweight from neutral

JPMorgan said the company is on the “road to redemption.”

“BP’s recent history has been chequered - operational inconsistencies, strategic inconsistencies and a balance sheet poison pill. Now, macro tailwinds and micro renewal present a major opportunity to lower macro procyclicality and high-grade fundamentals into 2028.”

JPMorgan upgrades Graphic Packaging to overweight from neutral

JPMorgan said buy the weakness.

“With the shares now trading below 10x 2027 P/E and offering a dividend yield of ~5%, we find the return profile of GPK to be attractive and therefore upgrade our recommendation from Neutral to Overweight, but revise our Dec-2027 target price from $12.5/sh to $11.5/sh.”

Citi initiates Madrigal Pharmaceuticals as buy

Citi said the biotech company is compelling and undervalued.

“We are initiating coverage on Madrigal Pharma (MDGL) at Buy/HR with a target price of $725.”

Compass Point initiates FS Specialty Lending Fund as buy

Citi initiates Maze Therapeutics as buy

Citi said the biotech company has a slew of positive catalysts ahead.

“We initiate coverage on Maze Therapeutics at Buy/HR with a 12-month target price of $50.”

Needham initiates Belden as buy

Needham said the industrial tech company is a reshoring beneficiary.

“We initiate coverage of Belden, Inc. (BDC) with a Buy rating and $140 price target.”

Oppenheimer initiates The Toro Company as outperform

Oppenheimer said shares of the lawn maintenance company are compelling.

“We are initiating coverage on shares of The Toro Company ( TTC) with an Outperform rating and $120 price target.”